RESUMO
Capillary electrophoresis sodium dodecyl sulfate (CE-SDS) has emerged as an indispensable tool in biopharmaceutical analysis to supersede the conventional sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE). Despite the comparable migration behaviors of native proteins on the two platforms, the correlation has not been evaluated systematically for biotherapeutic proteins, which are often confounded by the presence of glycans and disulfides. Here we studied various mammalian glycoproteins using the two techniques under both reduced and non-reduced conditions. The results revealed substantial reduction in electrophoretic mobility under the capillary mode. Moreover, the migration order was found to be reversed between the reduced and nonreduced runs compared to SDS-PAGE. Such effects appeared to be independent of the content of sialylation. Our work unveiled complex interplays between the gel matrix, proteins and glycans which provide important guidance to biopharmaceutical analysis.
Assuntos
Dissulfetos/química , Glicoproteínas/análise , Polissacarídeos/química , Técnicas Biossensoriais , Eletroforese Capilar , Eletroforese em Gel de Poliacrilamida , Estrutura Molecular , Oxirredução , Espectrometria de Massas por Ionização e Dessorção a Laser Assistida por MatrizRESUMO
Recombinant human erythropoietin (EPO) is a therapeutic glycoprotein widely used for treating anemia. EPO glycans carry extensive sialylation and the level of the modification is known to affect receptor binding, protein stability and pharmacokinetics. Nonetheless, a detailed understanding of the effects of sialylation on EPO conformation and dynamics is still lacking. Here we investigate the changes to EPO dynamics following enzymatic trimming of terminal sialic acid by amide hydrogen deuterium exchange mass spectrometry (HDX-MS). The results revealed that desialylation enhances structural flexibility near the glycosylation sites, with greater effects observed around the O-glycosylation site relative to the N-glycosylation sites. The affected regions are surface-exposed loops connecting the helix bundle, which do not appear to reduce the thermostability of the molecule as revealed from melting measurement. Our findings demonstrate the feasibility of HDX-MS technique in deciphering the function of specific type of glycosylation that can provide novel insights into the role of sialylation on protein therapeutics.
Assuntos
Deutério/química , Eritropoetina/química , Hidrogênio/química , Proteínas Recombinantes/química , Sequência de Aminoácidos , Medição da Troca de Deutério/métodos , Glicosilação , Humanos , Espectrometria de Massas/métodos , Ácido N-Acetilneuramínico/química , Polissacarídeos/química , Ligação Proteica , Estabilidade ProteicaRESUMO
BACKGROUND: In contrast to pharmaceutical manufacturers, compounding pharmacies adhere to different quality-control standards, which may increase the likelihood of undetected outbreaks. In 2005, the Centers for Disease Control and Prevention received reports of cases of Serratia marcescens bloodstream infection occurring in patients who underwent cardiac surgical procedures in Los Angeles, California, and in New Jersey. An investigation was initiated to determine whether there was a common underlying cause. METHODS: A matched case-control study was conducted in Los Angeles. Case record review and environmental testing were conducted in New Jersey. The Centers for Disease Control and Prevention performed a multistate case-finding investigation; isolates were compared using pulsed-field gel electrophoresis analysis. RESULTS: Nationally distributed magnesium sulfate solution (MgSO(4)) from compounding pharmacy X was the only significant risk factor for S. marcescens bloodstream infection (odds ratio, 6.4; 95% confidence interval, 1.1-38.3) among 6 Los Angeles case patients and 18 control subjects. Five New Jersey case patients received MgSO(4) from a single lot produced by compounding pharmacy X; culture of samples from open and unopened 50-mL bags in this lot yielded S. marcescens. Seven additional case patients from 3 different states were identified. Isolates from all 18 case patients and from samples of MgSO(4) demonstrated indistinguishable pulsed-field gel electrophoresis patterns. Compounding pharmacy X voluntarily recalled the product. Neither the pharmacy nor the US Food and Drug Administration could identify a source of contamination in their investigations of compounding pharmacy X. CONCLUSIONS: A multistate outbreak of S. marcescens bloodstream infection was linked to contaminated MgSO(4) distributed nationally by a compounding pharmacy. Health care personnel should take into account the different quality standards and regulation of compounded parenteral medications distributed in large quantities during investigations of outbreaks of bloodstream infection.
Assuntos
Bacteriemia/epidemiologia , Fármacos Cardiovasculares/efeitos adversos , Surtos de Doenças , Contaminação de Medicamentos , Sulfato de Magnésio/efeitos adversos , Infecções por Serratia/etiologia , Serratia marcescens/patogenicidade , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Bacteriemia/microbiologia , Procedimentos Cirúrgicos Cardíacos , Centers for Disease Control and Prevention, U.S./estatística & dados numéricos , Infecção Hospitalar/epidemiologia , Infecção Hospitalar/microbiologia , Composição de Medicamentos/efeitos adversos , Composição de Medicamentos/normas , Feminino , Humanos , Los Angeles/epidemiologia , Masculino , Pessoa de Meia-Idade , New Jersey/epidemiologia , Fatores de Risco , Infecções por Serratia/epidemiologia , Serratia marcescens/isolamento & purificação , Estados UnidosRESUMO
Drug product specifications are a critical element of a good control strategy. Parenteral microsphere products are complex dosage forms, requiring careful development of test methods and acceptance criteria for the specifications. In particular, the in vitro release test method and acceptance criteria require rigorous scientific consideration and should be developed with an eye toward understanding the mechanisms of drug release. The final specifications need to ensure the safety, identity, strength, performance, and quality of the drug product at release and during storage through the end of its shelf-life. The specification limits are typically established based upon regulatory guidance, available data from the manufacturing process (process capability), from non-clinical, clinical, and stability studies.
Assuntos
Injeções , Microesferas , Preparações Farmacêuticas/normas , Preparações de Ação Retardada , Emulsões , Peso Molecular , Tamanho da Partícula , Polímeros/administração & dosagem , SolubilidadeRESUMO
Methylmalonic acidopathy resulting from severe methylmalonyl-CoA mutase deficiency causes acute, potentially lethal ketoacidotic episodes, renal failure, and acute and chronic neurologic disease. As dietary and alkali therapy is suboptimal, liver transplantation during infancy has been touted as a potential cure. However, reports in liver transplant recipients about new onset neurologic disease, in the absence of ketoacidosis, and progressive renal insufficiency have cast doubt about its effectiveness. We report the long-term (9 years) outcome for the first patient with severe methylmalonic acidopathy transplanted in the USA and provide new biochemical data that indicate why transplanted patients are still susceptible to "metabolic strokes". In our 10-year-old male patient, there is clear evidence that the de novo synthesis of propionyl-CoA within the CNS leads to brain methylmalonate (MMA) accumulation that is largely unaffected by transplantation. Liver replacement is not a cure for methylmalonic acidopathy.